An Evaluation on the Frequencies of Underlying Diseases and Symptoms Along with the Mortality Rate of COVID-19: A Systematic Review and Meta-Analysis

AbstractObjective:To estimate the attributable mortality, length of stay (LOS), and healthcare cost of pediatric and neonatal healthcare-acquired bloodstream infections (HA-BSIs).Design:A systematic review and meta-analysis.Methods:A systematic search (January 2000–September 2018) was conducted in PubMed, Cochrane, and CINAHL databases. Reference lists of selected articles were screened to identify additional studies. Case–control or cohort studies were eligible for inclusion when full text was available in English and data for at least 1 of the following criteria were provided: attributable or excess LOS, healthcare cost, or mortality rate due to HA-BSI. Study quality was evaluated using the Critical Appraisal Skills Programme Tool (CASP). Study selection and quality assessment were conducted by 2 independent researchers, and a third researcher was consulted to resolve any disagreements. Fixed- or random-effect models, as appropriate, were used to synthesize data. Heterogeneity and publication bias were evaluated.Results:In total, 21 studies were included in the systematic review and 13 studies were included in the meta-analysis. Attributable mean LOS ranged between 4 and 27.8 days; healthcare cost ranged between $1,642.16 and $160,804 (2019 USD) per patient with HA-BSI; and mortality rate ranged between 1.43% and 24%. The pooled mean attributable hospital LOS was 16.91 days (95% confidence interval [CI], 13.70–20.11) and the pooled attributable mortality rate was 8% (95% CI, 6–9). A meta-analysis was not conducted for cost due to lack of eligible studies.Conclusions:Pediatric HA-BSIs have a significant impact on mortality, LOS, and healthcare cost, further highlighting the need for implementation of HA-BSI prevention strategies.

Download Full-text

Chlorhexidine-Related Mortality Rate in Critically Ill Subjects in Intensive Care Units: A Systematic Review and Meta-Analysis

Respiratory Care ◽

10.4187/respcare.06434 ◽

2019 ◽

Vol 64 (3) ◽

pp. 337-349

Author(s):

Sojung Lee ◽

Nima Laghapour Lighvan ◽

Victoria McCredie ◽

Petros Pechlivanoglou ◽

Murray Krahn ◽

...

Keyword(s):

Systematic Review ◽

Intensive Care ◽

Mortality Rate ◽

Intensive Care Units ◽

Critically Ill ◽

Meta Analysis ◽

Related Mortality

Download Full-text

Acute Cardiac Injury and COVID-19 – A Systematic Review and Meta-analysis

10.21203/rs.3.rs-37704/v1 ◽

2020 ◽

Cited By ~ 1

Author(s):

Husam M Salah ◽

Angel Lopez Candales

Keyword(s):

Systematic Review ◽

Mortality Rate ◽

Meta Analysis ◽

Cardiac Injury ◽

Case Series ◽

Common Finding ◽

Full Spectrum ◽

Global Pandemic ◽

Current Prevalence ◽

Case Series Study

Abstract Introduction:The ongoing global pandemic, coronavirus disease 2019 (COVID-19), an illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has ranged from an asymptomatic state to unprecedented number of deaths worldwide. In symptomatic patients, a viral pneumonia can unrelentingly progress to multi-system failure with preferential cardiac tropism. Although the full spectrum of COVID-19 cardiac manifestations is still not clear; acute cardiac injury (ACI) remains a common finding. The goal of our study, not only is to examine the current prevalence of ACI among COVID-19 infected patients but also, the reported mortality.Method:After thoroughly searching the literature for appropriate studies, a systematic review and meta-analysis were performed. Inclusion criteria were 1) Cohort study, case-control study, or case series study. 2) The study population included individuals with COVID-19 3) The presence or absence of cardiac injury was reported in the study 4) Mortality among patients with cardiac injury is reported or can be calculated.Results:Ten studies were included with a total of 1664 patients. The prevalence of ACI was 30.8%. The mortality rate among patients with concurrent COVID-19 and ACI was 53%.Conclusion:ACI can occur in one third of patients with COVID-19. Concurrent COVID-19 and ACI entails a high mortality rate. Serum troponin level can be a good prognostic tool in COVID-19.

Download Full-text

Risk factors for severe corona virus disease 2019 (COVID-19) patients : a systematic review and meta analysis

10.1101/2020.03.30.20047415 ◽

2020 ◽

Cited By ~ 18

Author(s):

Lizhen Xu ◽

Yaqian Mao ◽

Gang Chen

Keyword(s):

Risk Factors ◽

Systematic Review ◽

Virus Disease ◽

Meta Analysis ◽

High Body Mass Index ◽

Elderly Male ◽

Corona Virus ◽

Laboratory Test Results ◽

Male Patients ◽

Underlying Diseases

AbstractImportanceWith the increasing number of infections for COVID-19, the global health resources are deficient. At present, we don’t have specific medicines or vaccines against novel coronavirus pneumonia (NCP) and our assessment of risk factors for patients with severe pneumonia was limited. In order to maximize the use of limited medical resources, we should distinguish between mild and severe patients as early as possible.ObjectiveTo systematically review the evidence of risk factors for severe corona virus disease 2019 (COVID-19) patients.Evidence ReviewWe conducted a comprehensive search for primary literature in both Chinese and English electronic bibliographic data bases including China National Knowledge Infrastructure (CNKI), Wanfang, Weipu, Chinese Biomedicine Literature Database (CBM-SinoMed), MEDLINE (via PubMed), EMBASE, Cochrane Central Register, and Web of science. The American agency for health research and quality (AHRQ) tool were used for assessing risk of bias. Mata-analysis was undertaken using STATA version 15.0.Results20 articles (N=4062 participants) were eligible for this systematic review and meta-analysis. First in this review and meta-analysis, we found that elderly male patients with a high body mass index, high breathing rate and a combination of underlying diseases (such as hypertension, diabetes, cardiovascular disease, and chronic obstructive pulmonary disease) were more likely to develop into critically ill patients. second, compared with ordinary patients, severe patients had more significant symptom such as fever and dyspnea. Besides, the laboratory test results of severe patients had more abnormal than non-severe patients, such as the elevated levels of white-cell counts, liver enzymes, lactate dehydrogenase, creatine kinase, c-reactive protein and procalcitonin, etc, while the decreased levels of lymphocytes and albumin, etc.InterpretationThis is the first systematic review investigating the risk factors for severe corona virus disease 2019 (COVID-19) patients. The findings are presented and discussed by different clinical characteristics. Therefore, our review may provide guidance for clinical decision-making and optimizes resource allocation.Key PointsQuestionWhat are the risk factors for severe patients with corona virus disease 2019 (COVID-19)?FindingsFirst in this review and meta-analysis, we found that elderly male patients with a high body mass index, high breathing rate and a combination of underlying diseases were more likely to develop into critically ill patients. second, compared with ordinary patients, severe patients had more significant symptom such as fever and dyspnea. Last, we also found that the laboratory test results of severe patients had more abnormal than non-severe patients.MeaningThis review summaried the risk factors of severe COVID-19 patients and aim to provide a basis for early identification of severe patients by clinicians.

Download Full-text

Anti-Xa versus time-guided anticoagulation strategies in extracorporeal membrane oxygenation: a systematic review and meta-analysis

Perfusion ◽

10.1177/0267659120952982 ◽

2020 ◽

pp. 026765912095298

Author(s):

Ariane Willems ◽

Peter P Roeleveld ◽

Sonia Labarinas ◽

John W Cyrus ◽

Jennifer A Muszynski ◽

...

Keyword(s):

Systematic Review ◽

Mortality Rate ◽

Extracorporeal Membrane Oxygenation ◽

Observational Studies ◽

Meta Analysis ◽

Lower Mortality ◽

Bleeding Events ◽

Membrane Oxygenation ◽

Significant Difference

The purpose was to compare time-based vs anti-Xa-based anticoagulation strategies in patients on ECMO. We conducted a systematic review and meta-analysis using multiple electronic databases and included studies from inception to July 19, 2019. The proportion of bleeding, thrombosis, and mortality were evaluated. Twenty-six studies (2,086 patients) were included. Bleeding occurred in 34.2% (95%CI 25.1;43.9) of the patients with anti-Xa-based versus 41.6% (95%CI 24.9;59.4) of the patients with time-based anticoagulation strategies. Thrombosis occurred in 32.6% (95%CI 19.1;47.7) of the patients with anti-Xa-based versus 38.4% (95%CI 22.2;56.1) of the patients with time-based anticoagulation strategies. And mortality rate was 35.4% (95%CI 28.9;42.1) of the patients with anti-Xa-based versus 42.9% (95%CI 36.9;48.9) of the patients with time-based anticoagulation strategies. Among the seven studies providing results from both anticoagulation strategies, significantly fewer bleeding events occurred in the anti-Xa-based anticoagulation strategy (adjusted OR 0.49 (95%CI 0.32;0.74), p < 0.001) and a significantly lower mortality rate (adjusted OR 0.61 (95%CI 0.40;0.95), p = 0.03). There was no significant difference in thrombotic events (adjusted OR 0.91 (95%CI 0.56;1.49), p = 0.71). In these seven observational studies, only a small fraction of the patients were adults, and data were insufficient to analyze the effect of the type of ECMO. In this meta-analysis of observational studies of patients on ECMO, an anti-Xa-based anticoagulation strategy, when compared to a time-based strategy, was associated with fewer bleeding events and mortality rate, without an increase in thrombotic events.

Download Full-text

Statins Use and Risk of Breast Cancer Recurrence and Death: A Systematic Review and Meta-Analysis of Observational Studies

Journal of Pharmacy & Pharmaceutical Sciences ◽

10.18433/j3202b ◽

2016 ◽

Vol 19 (1) ◽

pp. 72 ◽

Cited By ~ 23

Author(s):

Marjan Mansourian ◽

Shaghayegh Haghjooy-Javanmard ◽

Azadeh Eshraghi ◽

Golnaz Vaseghi ◽

Alireza Hayatshahi ◽

...

Keyword(s):

Breast Cancer ◽

Systematic Review ◽

Mortality Rate ◽

Cohort Studies ◽

Randomized Clinical Trials ◽

Meta Analysis ◽

Cancer Recurrence ◽

Breast Cancer Recurrence ◽

Breast Cancer Patients ◽

Reduce Mortality Rate

Purpose. Statins are widely prescribed drugs for lowering cholesterol. Some studies have suggested that statins can prevent breast cancer recurrence and reduce mortality rate. However they are not conclusive. Present systematic review and meta-analysis of published cohort studies was conducted to determine the effects of statins intake and risk of breast cancer recurrence and mortality rate. Methods. Online databases (PubMed, Embase, Scopus, EBSCO and Cochrane Collaboration) were searched through October 2014. Pooled relative risks and 95 % confidence intervals were calculated with random-effects. Results. A total of 8 cohort studies (4 for recurrence 2 for mortality and 2 for both) involving 124669 participants with breast cancer were eligible. Our results suggest a significant reduction in recurrence (OR= 0.79. I2= 38%) and death (OR = 0.84, I2 = 8.58 %) among statin users. Conclusion. Our meta-analysis suggests that breast cancer patients will benefit from statin intake, however from these cohorts we are unable to differentiate between various statins in terms of effectiveness and duration of use. We highly propose conducting randomized clinical trials. This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.

Download Full-text

A Systematic Review and Meta-analysis of the Mortality Rate of Electroconvulsive Therapy (ECT)

10.26226/morressier.5885d719d462b8028d893004 ◽

2017 ◽

Author(s):

Soren Dinesen Ostergaard

Keyword(s):

Systematic Review ◽

Mortality Rate ◽

Electroconvulsive Therapy ◽

Meta Analysis

Download Full-text

Is Percutaneous Endoscopic Gastrostomy Tube Feeding Beneficial for Improving Survival in Patients With Dementia? A Systematic Review and Meta-Analysis of Current Pieces of Evidence

ACTA MEDICA IRANICA ◽

10.18502/acta.v60i1.8322 ◽

2022 ◽

Author(s):

Shima Raeesi ◽

Rezvan Hashemi ◽

Zahra Vahabi ◽

Mina Abdolahi ◽

Mohsen Sedighiyan

Keyword(s):

Systematic Review ◽

Mortality Rate ◽

Median Survival ◽

Percutaneous Endoscopic Gastrostomy ◽

Weighted Mean Difference ◽

Meta Analysis ◽

Tube Feeding ◽

Nutritional Deficiencies ◽

Percutaneous Endoscopic Gastrostomy Tube ◽

Endoscopic Gastrostomy

Dementia is a progressive, disabling neurogenic disease that results in serious nutritional deficiencies included dysphagia, malnutrition, and weight loss. The Percutaneous Endoscopic Gastrostomy (PEG) is a long-term enteral feeding method that is routinely used in demented patients with poor food intake as a standard protocol. However, most of the pieces of evidence have not shown the beneficial effects of PEG feeding on complications or survival rates in these patients. Some studies have even reported an increase in mortality. The current systematic review and meta-analysis aimed to evaluate the mortality rate and survival in primary demented patients with PEG. A systematic search was conducted on Pubmed and Scopus databases up to Aug 2019. The data were reviewed according to the Cochrane handbook and preferred reporting items for systematic reviews and meta-analyses (PRISMA) and meta-analysis of observational studies in epidemiology (MOOSE). Based on the random-effects model, the mortality rate and median survival were expressed as risk ratio and weighted mean difference (WMD) and 95% CI, respectively. Among 13 included studies, PEG insertion in patients with primary dementia has no significant effect on 30-day, 90-day, 180-day, 1-year, and 2- year mortality rate or median survival (WMD: 9.77; 95% CI: -22.43 to 41.98; P=0.55). It seems that nasogastric tube (NGT) feeding in compared to PEG in this population is more effective. In conclusion, further prospective studies are needed for comprehensive evaluation of mortality or survival regarding comorbidities, underlying disease, cognitive and physical performance, and nutritional problems in demented patients.

Download Full-text